Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 100
Filter
1.
Ann Diagn Pathol ; 4(3): 135-42, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10919382

ABSTRACT

Alveolar soft part sarcoma (ASPS) is a rare malignant neoplasm characterized by slow growth and indolent behavior. The role of proliferative markers and tumor suppressor genes is unknown in these tumors. To investigate their potential role in diagnosis and prognosis, we studied 13 cases of primary ASPS and 14 metastases and correlated them with clinicopathologic parameters. Immunohistochemistry was performed with anti-p53 and anti-Ki-67 antibodies. Polymerase chain reaction after tumor microdissection was performed to search for possible loss of heterozygosity in chromosomes 1p, 9p, 17q, 22q, and TP53 to identify possible changes that may clarify the histogenesis of these tumors. Four of five (80%) primary ASPS cases were positive for Ki-67 and all of them developed later metastases. One patient whose tumor did not stain for Ki-67 remained free of disease for 9 years. Eleven of 13 (85%) metastases were positive for Ki-67; however, there was no correlation with final outcome. All the primary ASPS cases analyzed for p53 yielded negative results, but two (15%) of 13 metastases were weakly positive. There was no correlation of these markers with prognosis or clinicopathologic parameters. No loss of heterozygosity was found except in one of nine (11%) informative metastases for D1S165 (at 1p36). Our preliminary data suggest that Ki-67-positive immunostaining may be a prognostic indicator for the development of metastases in ASPS.


Subject(s)
Biomarkers, Tumor/analysis , Sarcoma, Alveolar Soft Part/metabolism , Adolescent , Adult , Child , Female , Genes, p53 , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Loss of Heterozygosity , Male , Middle Aged , Polymerase Chain Reaction , Prognosis , Sarcoma, Alveolar Soft Part/genetics , Sarcoma, Alveolar Soft Part/secondary , Tumor Suppressor Protein p53/analysis , Tumor Suppressor Protein p53/genetics
2.
Hum Pathol ; 31(2): 233-8, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10685639

ABSTRACT

Loss of heterozygosity (LOH) of tumor suppressor genes (TSGs) in ovarian epithelial tumors of differing cell types and biological behavior has not been thoroughly investigated. Moreover, there have been conflicting reports correlating LOH of the p53 gene to overexpression of p53 protein. This study evaluated 34 formalin-fixed, paraffin-embedded ovarian epithelial tumors for LOH by polymerase chain reaction (PCR) for the following microsatellite markers: TP53(17p13.1/p53 gene), D17S579(17q/BRCA1 gene), and ESR (6q24-27/estrogen receptor gene). LOH of the TP53 marker was detected in 4 (44%) of 9 informative serous cystadenocarcinomas (SCa) but in 0 of 4 informative clear cell carcinomas (CCa) and 0 of 5 informative serous tumors of low malignant potential (SLMP). LOH of the BRCA1 marker was detected in 5 (83%) of 6 informative SCa, but in 1 (13%) of 8 informative CCa and 1 (14%) of 7 informative SLMP. LOH of the ESR marker was detected in 4 (50%) of 8 informative SCa, but in 0 of 4 informative CCa and 1 (16%) of 6 informative SLMP. p53 protein overexpression was present in 8 of 12 SCa but did not correlate to TP53 LOH. LOH for TP53, D17S579/ BRCA1, and ESR is common in ovarian SCa, and is observed in primary tumors as well as metastases. In contrast, these genetic alterations are less common in CCa and in the biologically less aggressive SLMP tumors. These data suggest different mechanisms of oncogenesis in ovarian epithelial tumors of different cell types and biological behavior.


Subject(s)
BRCA1 Protein/genetics , Gene Expression , Genes, p53 , Loss of Heterozygosity , Ovarian Neoplasms/genetics , Receptors, Estrogen/genetics , Adenocarcinoma, Clear Cell/genetics , Cystadenocarcinoma, Serous/genetics , Female , Humans , Microsatellite Repeats , Polymerase Chain Reaction
4.
Breast Cancer Res ; 2(4): 237-40, 2000.
Article in English | MEDLINE | ID: mdl-11250713

ABSTRACT

The use of human tissue, and material derived from such tissue, for research purposes is currently the subject of much debate. This debate needs to address several issues, including: the principle of abandonment; the distinction between identified and unidentified specimens; general versus specific informed consent; and, with the improvement in biotechnology and medical informatics, the design and security of research databases. The outcome of this debate will shape the way in which research studies using human biological materials are designed and executed.


Subject(s)
Breast Neoplasms/pathology , Ownership/legislation & jurisprudence , Patient Advocacy/legislation & jurisprudence , Research/legislation & jurisprudence , Cell Culture Techniques , Confidentiality , Culture Techniques , Female , Forms and Records Control , Humans , Informed Consent , Public Opinion , Research Design , Research Support as Topic , Tissue Preservation , Tumor Cells, Cultured , United Kingdom , United States
5.
Pathol Res Pract ; 195(10): 677-80, 1999.
Article in English | MEDLINE | ID: mdl-10549031

ABSTRACT

Lung cancer is the leading cause of death in both women and men in the United States and many European countries. Molecular cytogenetic and LOH analyses of non-small cell lung cancer have shown somatic genetic alterations in a variety of chromosomes, such as 1p, 3p, 5q, 8p, 9p, 11p, 11q and 17p. Allelic deletions of the known tumor suppressor gene APC at 5q21 are frequently observed in advanced stages of lung cancer and have been correlated with poor prognosis in previous reports. We investigated 33 cases of NSCL for LOH at 5q21: 22 squamous cell and 11 adenocarcinomas. Normal and tumor cells were microdissected from paraffin embedded tissues and PCR amplification was performed utilising the specific markers D5S299 and D5S346 at 5q21 and PYGM at 11q13, respectively. Clinicopathological data, survival and recurrence rates were obtained in all cases. We detected LOH at 5q21 in 4/9 (44%) informative adenocarcinomas and in 13/16 (81%) informative SCC. LOH was frequent in early stages (12/15 stage I cases) and did not correlate with recurrence or poor survival. Our results show that LOH at 5q21 is more frequent in squamous cell carcinomas than in adenocarcinomas, is frequent in early stages of the disease, and does not have prognostic significance.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Chromosomes, Human, Pair 5/genetics , Cytoskeletal Proteins/genetics , Loss of Heterozygosity/genetics , Lung Neoplasms/genetics , Adenocarcinoma/genetics , Adenocarcinoma/mortality , Adenomatous Polyposis Coli Protein , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/mortality , Female , Genetic Markers , Humans , Lung Neoplasms/mortality , Male , Middle Aged , Survival Rate
6.
Arch Pathol Lab Med ; 123(11): 1076-8, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10539912

ABSTRACT

Recent advances in molecular pathology and molecular genetics have created new concerns about the use of human biologic materials in research. Since researchers now have the ability to extract and amplify DNA from minuscule archived samples, virtually any human tissue sample can potentially become the template for a test that provides information that may relate to the inherited genes of an individual. Researchers using human biologic materials should follow the 3 basic principles that have been defined for all ethical human subjects research: respect for persons, beneficence, and justice. Institutional Review Boards are responsible for providing review of the risks and benefits of research proposals to safeguard the rights and welfare of human subjects. Currently, there is considerable debate concerning the role of informed consent procedures and the Institutional Review Board oversight process in situations when researchers use human biologic materials that have been anonymized or coded. In 1999, the National Bioethics Advisory Commission is expected to make recommendations to President Clinton and the National Science and Technology Council that are expected to clarify the balance between respect for personal autonomy and the societal need to pursue biomedical research to improve the health and welfare of all individuals.


Subject(s)
Ethics, Medical , Genetic Techniques , Pathology, Clinical , Human Experimentation/legislation & jurisprudence , Humans , Informed Consent , United States
7.
Int J Gynecol Pathol ; 18(4): 320-4, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10542939

ABSTRACT

The association of endometrial carcinoma with other gynecologic neoplasms, especially ovarian and fallopian tube carcinoma, has been well documented and is usually interpreted as a result of a field defect. Sporadic synchronous primary carcinomas occurring in the endometrium and colon are extremely rare, especially in the absence of the familial genetic abnormalities seen in hereditary nonpolyposis colorectal carcinoma (HNPCC) syndrome, and may present a diagnostic dilemma. Two cases of synchronous adenocarcinomas of the endometrium and colon were studied for genetic abnormalities and differences to test for the presence of two primary tumors. Primary tumors, metastases, and normal tissues were microdissected from formalin-fixed, paraffin-embedded tissues. PCR amplification was performed for microsatellite DNA markers on chromosome 17q and 11q13. The colonic tumors were moderately and poorly differentiated, invasive, nonmucinous adenocarcinomas, whereas one uterine tumor was endometrioid adenocarcinoma and the other was papillary serous carcinoma. Although microsatellite instability, as evidenced by changes in the lengths of the amplified PCR products, was detected at 17q and 11q13 loci in the uterine and colonic neoplasms, the patterns of instability differed between the two primary tumor sites. Moreover, the lymph node metastasis in one colonic tumor had genetic alterations that differed from that of the primary tumor. In both patients, the molecular studies suggested the presence of two synchronous primary tumors. Molecular techniques may assist in distinguishing two separate primaries by determining the contraction and expansion of microsatellite regions in DNA obtained by microdissection from the primary tumors and associated metastases.


Subject(s)
Adenocarcinoma/genetics , Colonic Neoplasms/genetics , Endometrial Neoplasms/genetics , Microsatellite Repeats/genetics , Neoplasms, Multiple Primary/genetics , Adenocarcinoma/diagnosis , Aged , Aged, 80 and over , Alleles , Autoradiography , Colonic Neoplasms/diagnosis , Diagnosis, Differential , Electrophoresis, Polyacrylamide Gel , Endometrial Neoplasms/diagnosis , Female , Humans , Neoplasms, Multiple Primary/diagnosis , Polymerase Chain Reaction
8.
9.
Cancer ; 87(4): 238-42, 1999 Aug 25.
Article in English | MEDLINE | ID: mdl-10455213

ABSTRACT

BACKGROUND: The Tall cell variant of papillary carcinoma of the thyroid (TCV) is characterized by the proliferation of oxyphilic, tall, columnar cells with a height-to-width ratio of at least 2:1. TCV exhibits more aggressive clinical behavior than conventional thyroid papillary carcinoma (CPC). Cytologic features suggestive of TCV have been described in fine-needle aspiration material from primary tumors. Similarly, loss of heterozygosity (LOH) for chromosome 1 (D1S243) and the p53 gene (TP53) have been reported in TCV but not in CPC, thus making exploitation of this genetic feature a potential tool for molecular discrimination between these two neoplasms. METHODS: Cytology samples of metastatic and/or recurrent neoplasms (M/R) (12 cases) and 7 cases of primary TCV obtained from 12 patients were evaluated. The cytologic findings of these cases were compared with previously published findings. Microdissection and polymerase chain reaction for LOH for chromosome 1 and p53 (D1S243 and TP53 markers) were performed on cytologic smears from 6 cases of M/R tumors and 3 cases of primary tumors. RESULTS: More then 50% of M/R showed atypical follicular cells with enlarged nuclei, granular chromatin, nuclear grooves, pseudoinclusions, and abundant finely granular cytoplasm. Cells were disposed in monolayers (58%) and papillary clusters (50%). Similar findings were present in cases of primary TCV. LOH studies showed that 4 of 6 M/R were noninformative and 2 of 3 cases of primary TCV were informative for the D1S243 marker; however, in contrast with previously published reports, no LOH was detected for the markers evaluated. CONCLUSIONS: M/R and primary TCV have similar cytologic features. Additional studies of larger series of M/R and primary TCV should be performed to delineate further any potential application of LOH for chromosome 1 and the p53 gene as a tool for diagnosing TCV with cytologic preparations. Cancer (Cancer Cytopathol)


Subject(s)
Carcinoma, Papillary/genetics , Loss of Heterozygosity/genetics , Neoplasm Recurrence, Local/genetics , Thyroid Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Carcinoma, Papillary/secondary , Chromosomes, Human, Pair 1/genetics , DNA Mutational Analysis , DNA, Neoplasm/analysis , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Polymerase Chain Reaction , Thyroid Neoplasms/pathology , Tumor Suppressor Protein p53/analysis
10.
Mod Pathol ; 12(5): 499-504, 1999 May.
Article in English | MEDLINE | ID: mdl-10349988

ABSTRACT

Infiltrating micropapillary carcinoma of the breast is a recently described and poorly recognized aggressive variant of infiltrating ductal carcinoma for which the clinical significance and role of prognostic markers are not fully described. In 14 cases of infiltrating micropapillary carcinoma, we studied histologic characteristics; immunohistochemical expression of c-erbB-2, p53, and MIB-1; hormonal expression of these tumors; and genetic alterations on the p53 locus. We correlated these results with clinical outcome. Patient ages ranged from 37 to 58 years (mean, 50 yr). Nine patients presented with a palpable tumor, one with an axillary mass. Three patients had abnormal mammograms. Five patients (36%) presented with Stage II disease, eight (57%) with Stage III, and one (7%) with Stage IV. The tumors were a modified Bloom-Richardson Grade II in nine cases (64%) and Grade III in 5 (36%). Mitoses ranged from 1 to 12 per 10 high power fields. Necrosis was uniformly absent. Psammoma bodies were present in 9 cases (64%) and lymphatic invasion in 10 (71%). In all of the cases, c-erbB-2 was identified immunohistochemically, and MIB-I was positive, staining 30 to 60% of the tumor cells. The cells were immunoreactive for p53 in six (75%) of eight cases, and, when present, stained 20 to 50% of the tumor cells. Loss of heterozygosity on locus 17p13.1 (p53) was identified in 4 of 5 informative samples. Molecular and immunohistochemical analyses had an 80% concordance. Follow-up was available in 11 patients, of whom 9 had recurrence in the skin and chest wall (average time of recurrence, 24 mo). Recognition of this distinctive and aggressive variant of infiltrating carcinoma is important because of its unfavorable prognosis and specific pattern of local recurrence. Its aggressive nature is supported by its advanced stage at presentation and expression of unfavorable prognostic markers.


Subject(s)
Breast Neoplasms/diagnosis , Breast Neoplasms/pathology , Carcinoma, Papillary/diagnosis , Carcinoma, Papillary/pathology , Adult , Antigens, Nuclear , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Breast Neoplasms/mortality , Carcinoma, Papillary/genetics , Carcinoma, Papillary/metabolism , Carcinoma, Papillary/mortality , Chromosomes, Human, Pair 17/genetics , Female , Humans , Immunohistochemistry , Ki-67 Antigen , Loss of Heterozygosity/genetics , Middle Aged , Nuclear Proteins/metabolism , Polymerase Chain Reaction , Prognosis , Receptor, ErbB-2/metabolism , Survival Rate , Tumor Suppressor Protein p53/metabolism
11.
J Clin Endocrinol Metab ; 84(6): 2086-92, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10372715

ABSTRACT

The expression of integrin laminin receptors was investigated in normal thyroid primary cultures; immortalized normal thyroid cells (TAD-2); papillary (NPA), follicular (WRO), and anaplastic (ARO) thyroid tumor cell lines; seven thyroid tumors (four papillary and three follicular carcinomas); and normal thyroid glands. The expression of alpha1beta1, alpha2beta1, alpha3beta1, alpha6beta1, and alpha6beta4 was found in all tumor specimens and in tumor cell lines, whereas normal thyroid cells and TAD-2 cells lacked the expression of alpha6beta4. Despite the presence of several integrin laminin receptors, adhesion of TAD-2, NPA, and ARO cells to immobilized laminin-1 was poor, whereas WRO cells and follicular carcinoma-derived cells displayed a strong adhesion. Indeed, WRO and follicular carcinoma-derived cells showed expression of a nonintegrin laminin receptor, the 67-kDa high affinity laminin receptor (67LR). TAD-2, NPA, and ARO cells as well as nodular goiter, toxic adenoma, follicular adenoma, and papillary carcinoma-derived cells did not express the 67LR. Adhesion of WRO and follicular carcinoma-derived cells to laminin-1 was specifically inhibited by a recombinant polypeptide containing laminin-binding domains of 67LR, demonstrating that this receptor confers to follicular carcinoma cells attachment capacity to laminin. Moreover, tissue specimens from follicular carcinomas expressed the 67LR, whereas follicular adenomas and normal thyroid tissues were negative. In thyroid tumors, integrin receptors, although abundant, participate weakly in adhesion to laminin. The expression in follicular carcinoma cells of a functional, high affinity 67LR together with nonfunctional integrin LM receptors could be responsible for the tendency of follicular carcinoma cells to metastasize by mediating stable contacts with basal membranes.


Subject(s)
Adenocarcinoma, Follicular/metabolism , Protein Precursors , Receptors, Laminin/biosynthesis , Thyroid Neoplasms/metabolism , Biotin/metabolism , Blotting, Western , Cell Adhesion , Flow Cytometry , Humans , Laminin/physiology , Precipitin Tests , Thyroid Gland/metabolism , Thyroid Gland/pathology , Tumor Cells, Cultured
12.
Arch Pathol Lab Med ; 123(4): 296-300, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10320140

ABSTRACT

As recipients of tissue and medical specimens, pathologists and other medical specialists regard themselves as stewards of patient tissues and consider it their duty to protect the best interests of both the individual patient and the public. The stewardship of slides, blocks, and other materials includes providing, under appropriate circumstances, patient materials for research, education, and quality control. The decision to provide human tissue for such purposes should be based on the specific (ie, direct patient care) and general (ie, furthering medical knowledge) interests of the patient and of society. The same standards of responsibility should apply to all medical professionals who receive and use specimens. This document proposes specific recommendations whereby both interests can be fostered safely, ethically, and reasonably.


Subject(s)
Education, Medical , Ethics, Medical , Quality Control , Biological Specimen Banks , Culture Techniques , Humans , Informed Consent , Tissue Donors
13.
J Cell Biochem ; 71(1): 46-54, 1998 Oct 01.
Article in English | MEDLINE | ID: mdl-9736453

ABSTRACT

Homeodomain-containing proteins regulate, as transcription factors, the coordinated expression of genes involved in development, differentiation, and malignant transformation. We report here the molecular cloning of a mutated HOXB7 transcript encoding a truncated homeodomain-containing protein in MCF7 cells. This is a new example of mutation affecting the coding region of a HOX gene. In addition, we detected two HOXB7 transcripts in several breast cell lines and demonstrated that both normal and mutated alleles were expressed at the RNA level in MCF7 cells as well as in a variety of breast tissues and lymphocytes, suggesting that a truncated HOXB7 protein might be expressed in vivo. Using transient co-transfection experiments, we demonstrated that both HOXB7 proteins can activate transcription from a consensus HOX binding sequence in breast cancer cells. Our results provide evidence that HOXB7 protein has transcription factor activity in vivo and that the two last amino acids do not contribute to this property.


Subject(s)
Breast Neoplasms/metabolism , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Mutation , Breast Neoplasms/genetics , Cloning, Molecular , Codon, Terminator , DNA, Complementary , Humans , Transcription, Genetic , Tumor Cells, Cultured
14.
Mol Biol Evol ; 15(8): 1017-25, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9718729

ABSTRACT

The 67-kDa laminin receptor (67LR) is a nonintegrin cell surface receptor that mediates high-affinity interactions between cells and laminin. Overexpression of this protein in tumor cells has been related to tumor invasion and metastasis. Thus far, only a full-length gene encoding a 37-kDa precursor protein (37LRP) has been isolated. The finding that the cDNA for the 37LRP is virtually identical to a cDNA encoding the ribosomal protein p40 has suggested that 37LRP is actually a component of the translational machinery, with no laminin-binding activity. On the other hand, a peptide of 20 amino acids deduced from the sequence of 37LR/p40 was shown to exhibit high laminin-binding activity. The evolutionary relationship between 23 sequences of 37LRP/p40 proteins was analyzed. This phylogenetic analysis indicated that all of the protein sequences derive from orthologous genes and that the 37LRP is indeed a ribosomal protein that acquired the novel function of laminin receptor during evolution. The evolutionary analysis of the sequence identified as the laminin-binding site in the human protein suggested that the acquisition of the laminin-binding capability is linked to the palindromic sequence LMWWML, which appeared during evolution concomitantly with laminin.


Subject(s)
Evolution, Molecular , Receptors, Laminin/genetics , Ribosomal Proteins/genetics , Amino Acid Sequence , Animals , Binding Sites/genetics , Humans , Laminin/metabolism , Molecular Sequence Data , Molecular Weight , Neoplasms/genetics , Phylogeny , Protein Precursors/chemistry , Protein Precursors/genetics , Protein Precursors/metabolism , Receptors, Laminin/chemistry , Receptors, Laminin/metabolism , Ribosomal Proteins/chemistry , Sequence Homology, Amino Acid
15.
J Cell Biochem ; 69(3): 244-51, 1998 Jun 01.
Article in English | MEDLINE | ID: mdl-9581863

ABSTRACT

Even though the involvement of the 67-kDa laminin receptor (67LR) in tumor invasiveness has been clearly demonstrated, its molecular structure remains an open problem, since only a full-length gene encoding a 37-kDa precursor protein (37LRP) has been isolated so far. A pool of recently obtained monoclonal antibodies directed against the recombinant 37LRP molecule was used to investigate the processing that leads to the formation of the 67-kDa molecule. In soluble extracts of A431 human carcinoma cells, these reagents recognize the precursor molecule as well as the mature 67LR and a 120-kDa molecule. The recovery of these proteins was found to be strikingly dependent upon the cell solubilization conditions: the 67LR is soluble in NP-40-lysis buffer whereas the 37LRP is NP-40-insoluble. Inhibition of 67LR formation by cerulenin indicates that acylation is involved in the processing of the receptor. It is likely a palmitoylation process, as indicated by sensitivity of NP-40-soluble extracts to hydroxylamine treatment. Immunoblotting assays performed with a polyclonal serum directed against galectin3 showed that both the 67- and the 120-kDa proteins carry galectin3 epitopes whereas the 37LRP does not. These data suggest that the 67LR is a heterodimer stabilized by strong intramolecular hydrophobic interactions, carried by fatty acids bound to the 37LRP and to a galectin3 cross-reacting molecule.


Subject(s)
Protein Precursors/metabolism , Receptors, Laminin/biosynthesis , Acylation , Antigens, Differentiation/chemistry , Cell Line , Chromatography, Affinity , Dimerization , Epitopes/chemistry , Fatty Acids/antagonists & inhibitors , Fatty Acids/biosynthesis , Galectin 3 , Humans , Hydroxylamine/chemistry , Laminin/metabolism , Protein Precursors/chemistry , Receptors, Laminin/chemistry , Receptors, Laminin/metabolism , Solubility
16.
J Cell Biochem ; 67(2): 155-65, 1997 Nov 01.
Article in English | MEDLINE | ID: mdl-9328821

ABSTRACT

The interactions between tumor cells and laminin or other components of the extracellular matrix have been shown to play an important role in tumor invasion and metastasis. These interactions are mediated by different cell surface molecules, including the monomeric 67 kD laminin receptor. This molecule appears to be very peculiar since so, far only a full-length gene encoding a 37 kD precursor protein has been isolated and the mechanism by which the precursor reaches the mature form is not understood. Based on clinical data, which clearly demonstrate the importance of the receptor in tumor progression, studies were conducted to define the structure, expression, and function of this laminin receptor as a step toward developing therapeutic strategies that target this molecule. The data suggest that acylation of the precursor is the key mechanism in maturation of the 67 kD form. The function of the membrane receptor is to stabilize the binding of laminin to cell surface integrins, acting as an integrin-accessory molecule, although homology of the gene encoding the receptor precursor with other genes suggests additional functions. Downregulation of the receptor expression on tumor cells might open new therapeutic approaches to decrease tumor aggressiveness.


Subject(s)
Neoplasm Metastasis , Receptors, Laminin , Animals , DNA, Complementary/chemistry , Gene Expression Regulation , Humans , Laminin/physiology , Neoplasms/genetics , Receptors, Laminin/biosynthesis , Receptors, Laminin/genetics , Receptors, Laminin/physiology , Sequence Homology
17.
Int J Biol Markers ; 12(1): 1-5, 1997.
Article in English | MEDLINE | ID: mdl-9176710

ABSTRACT

The 67-kDa laminin receptor (67LR) is an important tumor marker whose molecular structure has not yet been fully elucidated. To shed new light on this molecule, we raised a series of eight new monoclonal antibodies, designated MPLR1 to 8, directed against the 37-kDa recombinant laminin receptor precursor (37LRP). Cross-competition experiments demonstrated that the epitopes recognized by MPLR2, 4 and 5 partially overlap, since MPLR4 and 5 compete with labelled MPLR2 for the binding to recombinant 37LRP. These three antibodies belong to the IgG1 class, whereas the other ones are all IgM. Presumably due to the fact that they are directed against partially unfolded antigenic determinants expressed on the recombinant protein, MPLRs did not recognize the native protein. Indeed, they showed no reactivity at the membrane level in cytofluorimetric analysis and they did not work in immunoprecipitation experiments. In contrast, these reagents are valuable tools in immunoblotting, since they clearly identify a 67-kDa protein (the mature laminin receptor) in addition to the 37-kDa precursor form. MPLRs are thus a new powerful tool which could help in the characterization of the still enigmatic 67LR molecule.


Subject(s)
Antibodies, Monoclonal/immunology , Biomarkers, Tumor/immunology , Protein Precursors/immunology , Receptors, Laminin , Ribosomal Proteins/immunology , Animals , Antibodies, Monoclonal/biosynthesis , Binding, Competitive , Blotting, Western , Epitopes/immunology , Flow Cytometry , Fluorescent Antibody Technique, Indirect , Humans , Hybridomas/immunology , Mice , Mice, Inbred BALB C , Recombinant Proteins/immunology , Tumor Cells, Cultured
18.
J Pathol ; 181(1): 80-6, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9072007

ABSTRACT

Galectin-3 is a 31 kD beta-galactoside-binding lectin which is expressed by several types of non-neoplastic and neoplastic cells and which may be involved in cell-extracellular matrix interactions. An immunohistochemical study has been made of the expression of galectin-3, as well as its ligand, laminin, in a spectrum of benign and malignant thyroid neoplasms and in some non-neoplastic conditions. Immunohistochemistry with anti-human recombinant galectin-3 antibody showed consistent, intense positivity in the neoplastic cells of 18 cases of papillary carcinoma and less intense staining in the five anaplastic carcinomas studied. In addition, two out of three poorly differentiated carcinomas, three out of six medullary carcinomas, and four out of eight follicular carcinomas had less intense or focal positivity. One case of Hürthle cell carcinoma showed scattered strongly positive cells. Eight follicular adenomas, three hyperplastic nodules, five nodular goitres, and normal thyroid tissue were negative. Galectin-3 mRNA expression was also evaluated in three of the papillary carcinomas, two follicular adenomas, and one hyperplastic nodule with matched normal tissue. Northern blot analysis demonstrated mRNA overexpression in the three cases of papillary carcinomas, whereas normal and benign tissues were negative. Laminin distribution in neoplastic and non-neoplastic tissue varied with architectural patterns but did not correlate with galectin-3 immunohistochemical expression. We conclude that expression of galectin-3 is limited to inflammatory foci in normal and benign thyroid tissue and is a phenotypic feature of malignant thyroid neoplasms, especially papillary carcinomas.


Subject(s)
Antigens, Differentiation/metabolism , Biomarkers, Tumor/metabolism , Laminin/metabolism , Thyroid Gland/metabolism , Thyroid Neoplasms/metabolism , Antigens, Differentiation/genetics , Blotting, Northern , Galectin 3 , Gene Expression , Humans , Immunoenzyme Techniques , RNA, Messenger/genetics , RNA, Neoplasm/genetics , Thyroid Diseases/metabolism
19.
DNA Cell Biol ; 15(12): 1009-23, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8985115

ABSTRACT

A 37LRP/p40 polypeptide is of major interest because it is consistently up-regulated in cancer cells in correlation with their invasive and metastatic phenotype. Furthermore, this polypeptide presents intriguing multifunctional properties because it has been characterized as the precursor of the metastasis-associated 67-kD laminin receptor (67LR) and as a cytoplasmic ribosomal-associated protein. The isolation of the 37LRP/p40 gene is a prerequisite for identifying the molecular mechanisms responsible for the constant up-regulation of the 67LR expression in cancer cells. To date, the active 37LRP/p40 gene has never been identified in any species due to the existence of multiple pseudogenes in most vertebrates genomes. In this study, we report for the first time the gene structure and potential regulatory sequences of the 37 LRP/p40 gene. The chicken genome was selected to undergo this characterization because it is the only known vertebrate that bears a single 37 LRP/p40 gene copy. The 37 LRP/p40 active gene is composed of 7 exons and 6 introns and bears features characteristic of a ribosomal protein gene. It does not bear a classical TATA box and it exhibits several transcription initiation sites as demonstrated by RNase protection assay and primer extension. Analysis of potential regulatory regions suggests that gene expression is driven not only by the 5' genomic region but also by the 5' untranslated and intron 1 sequences. On the basis of gene structure and extensive protein evolutionary study, we found that the carboxyterminal domain of the protein is a conserved lock-and-key structure/function domain that could be involved in the biosynthesis of the higher-molecular-weight 67-kD laminin receptor in vertebrates, whereas the central core of the protein would be responsible for the ribosome associated function. The first identification of the active 37LRP/p40 gene presented in this study is a critical step toward the isolation of the corresponding human gene and the understanding of the molecular mechanisms involved in the up-regulation of its expression during tumor invasion and metastasis.


Subject(s)
Genes/genetics , Protein Precursors/genetics , Receptors, Laminin , Amino Acid Sequence , Amino Acids , Animals , Base Sequence , Chickens , Cloning, Molecular , Gene Dosage , Humans , Molecular Sequence Data , Neoplasm Metastasis , Protein Precursors/chemistry , Protein Structure, Secondary , RNA, Messenger/analysis , Sequence Alignment , Sequence Analysis, DNA , Sequence Homology, Amino Acid , Transcription, Genetic/genetics
20.
Pathol Res Pract ; 192(12): 1206-10, 1996 Dec.
Article in English | MEDLINE | ID: mdl-9182290

ABSTRACT

The APC/MCC gene (Familial Adenomatous Polyposis) at 5q21 plays a role in colon cancer carcinogenesis. LOH at this locus has also been described in gastric cancer and preneoplastic lesions. The APC locus has been recently related to a cell surface adhesion molecule and its alteration may favour metastatic dissemination. LOH at 5q21 has been associated with poor prognosis in other tumors such as lung cancer. Thirty-six gastric cancers were evaluated for LOH at 5q21 with 2 polymorphic markers from microdissected paraffin-embedded material. All tumors were classified by stage, histologic type, degree of differentiation and survival rates. In 4 cases, intestinal metaplasia cells in the adjacent mucosae were also microdissected. Six cases of moderate-severe gastric dysplasia were also added to the study. LOH was determined in 84% of the informative cases of GC, affecting both early and advanced stages of disease. Genomic instability was assessed in 5 cases, 3 of them associated with LOH. The only case of gastric cancer that did not show LOH or instability at 5q21 was a stage II, poorly differentiated intestinal carcinoma without evidence of recurrence after a 36 month follow-up period (the mean survival rate in our series was 28.3% at 36 months). We also found LOH in 2/6 dysplastic lesions and 1/4 intestinal metaplasias. Our data show that LOH at 5q21 is frequent in gastric cancer and is also present in intestinal metaplasia and dysplastic lesions. LOH at this locus is not a prognostic factor in GC in our study, due to the high incidence of LOH that we found.


Subject(s)
Chromosome Deletion , Chromosomes, Human, Pair 5 , Genes, APC , Precancerous Conditions/genetics , Stomach Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Cell Differentiation , Female , Heterozygote , Humans , Male , Middle Aged , Neoplasm Staging , Polymerase Chain Reaction , Precancerous Conditions/diagnosis , Prognosis , Stomach Neoplasms/diagnosis , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...